Advertisement

 

 

Statins Tied to Reduced Mortality Risk in COPD

Statins Tied to Reduced Mortality Risk in COPD
Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

FRIDAY, Sept. 8, 2017 (HealthDay News) — Statin use is associated with a reduced risk of all-cause and pulmonary-related mortality in patients with chronic obstructive pulmonary disease (COPD), according to a study published online Sept. 7 in Chest.

Adam Raymakers, from the University of British Columbia in Canada, and colleagues evaluated the association of statin use with all-cause and pulmonary-related mortality in patients with COPD. They used individual prescription records to identify 39,678 COPD patients, of whom 7,775 had received at least one statin in the one-year period after COPD diagnosis.

The researchers found that there were 1,446 all-cause deaths recorded within the cohort in the one-year exposure window. In multivariate analysis, the estimated hazard ratio for statin exposure was 0.79, suggesting a 21 percent reduction in the risk of all-cause mortality. There was also a considerable reduction in the risk for pulmonary-related mortality (HR, 0.55).

“This study shows that statin use in a population-based cohort of COPD patients may confer benefits in terms of reduced pulmonary-related and all-cause mortality,” conclude the authors.

One author reports financial ties to the pharmaceutical industry.

Abstract/Full Text
Editorial

Copyright © 2017 HealthDay. All rights reserved.
healthday

Submit a Comment

Your email address will not be published. Required fields are marked *

3 × 2 =

[ HIDE/SHOW ]